Home | Publications | Treatments | Allergy / Colds place holder
place holder place holder

Allergy / Colds


Avian Influenza

The Threatening Pandemic

Publication Date   August 2006
Publisher   TriMark Publications
Product Type   Report
Pages   139
ISBN Number   TMRAVI06-0816
Product Code   TRI045
Ask a question about this product?

Price £990.00

approximately: $1,850 | €1,256

Summary


The purpose of this report is to describe the threatening world pandemic caused by avian influenza, also known as bird flu. This report discusses the origins of the disease, the bird-to-human infection risks, the catastrophic health crisis avian flu poses, and the efforts by world governments and international health organizations to mitigate of the impact the threat to humans. The U.S., Asia and Europe are the focus of this study. Primary attention is paid to the clinical market segment and, separately, to the medical procedures and supplies for the influenza infection control market. An analysis of the technology trends and developing areas of influenza infection science is provided, along with a review of the market for pharmaceutical agents, vaccines and hospital supplies in clinical use. Activity in research-including the factors that influence infection control-are addressed in this review. Also discussed are changes that have stimulated this disease and patterns of information processing in assessing its spread. Several subjects related to the major elements of influenza treatment such as disposable plastic supplies, needles and lancets are discussed only briefly because they are considered entirely different fields or markets. The goal of this report is to review the potential threat of a human influenza pandemic resulting from the avian flu virus. It defines the responses that are now being undertaken worldwide by governmental authorities to contain the spreading bird flu.

Content


  • 1. Overview
    • 1.1 Statement of Report
    • 1.2 About This Report
    • 1.3 Scope of the Report
    • 1.4 Objectives
    • 1.5 Methodology
    • 1.6 Executive Summary
  • 2. Introduction to Cancer Biology and the Diagnostic Industry
    • 2.1 Cancer
      • 2.1.1 The Disease
      • 2.1.2 Metastasis
      • 2.1.3 Demographics and Statistics of Cancer
    • 2.2 The Drivers of the Biotech and Diagnostics Industry
      • 2.2.1 Technological Innovation
      • 2.2.2 Government Funding
      • 2.2.3 Pharmaceutical Development
    • 2.3 Outlook for Tumor Markers
  • 3. Tumor Markers Market Segment Analysis: Size, Growth and Share
    • 3.1 Market Description
    • 3.2 Clinical Diagnostic Serum Based Cancer Markers
    • 3.3 PSA Testing Market Size
    • 3.4 DNA Markers
    • 3.5 Serum proteins
    • 3.6 Enzymes
    • 3.7 Occult Blood
    • 3.8 Histology and In Situ Hybridization (ISH)
    • 3.9 Cervical Cytology
    • 3.10 Immunohistochemistry
    • 3.11 In Vivo Detection Cancer Products
    • 3.12 Radionuclides and X-Ray Detection Products
    • 3.13 Human Papillomavirus (HPV) Testing
    • 3.14 Bladder Cancer Testing
  • 4. Diagnostic Methods for Cancer Detection
    • 4.1 Organ Specific Tumor Markers
      • 4.1.1 Colon Cancer
      • 4.1.2 Prostate Cancer
      • 4.1.3 Pancreatic Cancer
      • 4.1.4 Breast Cancer
      • 4.1.5 Ovarian Cancer
      • 4.1.6 Cervical Cancer
      • 4.1.7 Lung Cancer
      • 4.1.8 Testicular Cancer
      • 4.1.9 Bladder Cancer
      • 4.1.10 Hepatic Cancer
      • 4.1.11 Stomach Cancer
      • 4.1.12 Malignant Melanoma
      • 4.1.13 Acute Myeloid Leukemia (AML) and Acute Lymphoblastoid Leukaemia (ALL)
      • 4.1.14 Lymphoma
    • 4.2 Clinical Laboratory Methods for Measuring Tumor Markers
      • 4.2.1 Abbott Diagnostics AxSYM
      • 4.2.2 Roche Diagnostics Elecsys
      • 4.2.3 Beckman Coulter Diagnostics Access
      • 4.2.4 Bayer Diagnostics ADVIA Centaur
      • 4.2.5 Dade Diagnostics Stratus
      • 4.2.6 Diagnostic Products Corporation Immulite
      • 4.2.7 Tosoh Medics A1A
      • 4.2.8 CIS bio International Kryptor
      • 4.2.9 Ortho-Clinical DiagnosticsVitros ECiQ
      • 4.2.10 Fujirebio Diagnostics
      • 4.2.11 bioMrieux Vidas
      • 4.2.12 Eisai Picolumi
      • 4.2.13 TOSOH Medics
    • 4.3 New Technologies for Cancer Diagnostics
      • 4.3.1 New and Improved Immunoassays
      • 4.3.2 Immunohistochemical Tests
      • 4.3.3 Molecular (DNA and Genomic) Diagnostic Assays
      • 4.3.4 Genomics and Genetic Markers
      • 4.3.5 Proteomics and New Protein Markers
        • 4.3.5.1 Inside the ProteinChip System
        • 4.3.5.2 Rapid Biological Assays on a Chip
        • 4.3.5.3 Proteome Pattern Recognition
      • 4.3.6 New Platform Technologies Including Flow Cytometry
      • 4.3.7 Stem Cell Markers
      • 4.3.8 Monoclonal Antibodies
      • 4.3.9 Proteomics and Cancer Antibodies
      • 4.3.10 Pharmacogenomics and Oncology Diagnostics
      • 4.3.11 DNA Microarrays
      • 4.3.12 Future Directions
    • 4.4 Clinical Methods for Diagnosis of Cancer
      • 4.4.1 Screening
      • 4.4.2 Sigmoidoscopy
      • 4.4.3 Imaging
      • 4.4.4 Theranostics
  • 5. Implications of Molecular Biology for New Diagnostic Cancer Tests
  • 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms
    • 6.1 Abbott Diagnostics
    • 6.2 Affymetrix
    • 6.3 Agensys
    • 6.4 AMDL
    • 6.5 Arcturus Applied Genomics
    • 6.6 Aureon Biosciences
    • 6.7 Bard Diagnostics
    • 6.8 Bayer Diagnostics
    • 6.9 Beckman Coulter
    • 6.10 Biocode S.A.
    • 6.11 BioCurex
    • 6.12 Biomedical Diagnostics
    • 6.13 Biomerica
    • 6.14 bioMrieux
    • 6.15 Biomira
    • 6.16 BioModa
    • 6.17 Bruker Daltonics
    • 6.18 Byk Gulden
    • 6.19 Ciphergen Biosystems, Inc.
    • 6.20 Clarient, Inc.
    • 6.21 Correlogic Systems
    • 6.22 Cytogen
    • 6.23 Cytyc Corp.
    • 6.24 DiaDexus LLC
    • 6.25 Digene Corporation
    • 6.26 DiagnoCure
    • 6.27 Diagnostic Products Corporation
    • 6.28 Diagnostic Systems Laboratories Inc.
    • 6.29 DRG International
    • 6.30 Eisai Co., Ltd.
    • 6.31 Epigenomics
    • 6.32 Exact Sciences Corporation
    • 6.33 Gene Logic
    • 6.34 Genomic Health
    • 6.35 Geron Corporation
    • 6.36 Immunicon
    • 6.37 Immunomedics
    • 6.38 Incyte Pharmaceuticals
    • 6.39 LabCorp
    • 6.40 Matritech
    • 6.41 Mitsubishi Kagaku Medical
    • 6.42 Molecular Diagnostics, Inc.
    • 6.43 Myriad Genetics
    • 6.44 NeoRx Corp.
    • 6.45 Nexell Therapeutics
    • 6.46 Northwest Biotherapeutics, Inc.
    • 6.47 Nuvelo
    • 6.48 Oncotech, Inc.
    • 6.49 Polymedco
    • 6.50 Princeton BioMeditech Corporation
    • 6.51 Procyon BioPharma, Inc.
    • 6.52 Qiagen
    • 6.53 Sanko Junyaku Co., Ltd.
    • 6.54 Tosoh Medics
    • 6.55 TriPath Imaging
    • 6.56 UroCor, Inc.
    • 6.57 Ventana Medical Systems
    • 6.58 Veridex
    • 6.59 Worldwide Medical Corporation
  • 7. Business Trends in the Industry
    • 7.1 Industry Consolidation
    • 7.2 Breath of Product Offering and Pricing
    • 7.3 Government Regulation of Medical Devices
    • 7.4 Strategic Business and Marketing Considerations
    • 7.5 Commercial Opportunities in Cancer Markers
    • 7.6 Moderators of Growth
    • 7.7 Biotechnology Industry Trends
    • 7.8 Pharmaceutical Industry Trends
    • 7.9 Acquisition, License Agreement, Partnerships
    • 7.10 Legal Developments
    • 7.11 Sales and Marketing Strategies for Tumor Marker Tests
      • 7.11.1 North American Market
      • 7.11.2 International Markets
        • 7.11.2.1 Europe
        • 7.11.2.2 Central and South America
        • 7.11.2.3 Asia/Pacific
  • 8. Tumor Marker Testing: Important Issues
    • 8.1 Trends in Patient Care and Reimbursement
    • 8.2 Trends in Reimbursement Practice
    • 8.3 Clinical Laboratory Improvement Act (CLIA)
    • 8.4 Unmet Needs in Tumor Markers
  • 9. Important New Technology Areas
    • 9.1 Proteomics
    • 9.2 DNA Sequencing
    • 9.3 The Human Genome Project
    • 9.4 Liquid Phase Chromatography
    • 9.5 Polymerase Chain Reaction (PCR)
    • 9.6 Capillary Electrophoresis
    • 9.7 Proteomics
    • 9.8 Use of Mass Spectroscopy in Sequencing
    • 9.9 High-Throughput Organic Synthesis
  • 10. New Cancer Markers in Basic Research
    • 10.1 Genetics of Cancer
    • 10.2 Telomerase
    • 10.3 Stomach Cancer
    • 10.4 Head and Neck Cancer
    • 10.5 Breast Cancer
    • 10.6 Prostate Cancer: p27 (kip1) A New Molecular Marker For Prostate Cancer
    • 10.7 PSMA
    • 10.8 Cervical Cancer: NMPI79
    • 10.9 Pancreatic Cancer: Peritoneal Cytology
    • 10.10 Colorectal Cancer: CEA Doubling Time
    • 10.11 Uterine and Kidney Cancer: MN/CA9
    • 10.12 MMSC1 Scaffold Gene
    • 10.13 p16 Tumor Suppressor Gene
    • 10.14 MTS2 and p19 Cell Cycle Genes
    • 10.15 Complement Factor H Related Proteins
    • 10.16 MUC 2, 3, 4
    • 10.17 Cytokeratins
    • 10.18 Colon Cancer: Serum VEGF
    • 10.19 Ras Oncogenes
    • 10.20 Lung Cancer: Ribonucleoprotein A2/B1
    • 10.21 BCLA-4 Matrix Protein
    • 10.22 RAK Antigens
    • 10.23 Serum Urokinase Receptors
    • 10.24 Chips
    • 10.25 Survivin
    • 10.26 Endometrial Specific Steroid Binding Factor (hESF1)
    • 10.27 Reg-4 Protein
    • 10.28 Nox-1
    • 10.29 PSP94 Binding Protein
    • 10.30 Ettan DIGE Technology
    • 10.31 YKL-40
    • 10.32 AFP-L3
    • 10.33 DNA Methylation Technology
    • 10.34 Transthyretin and Apolipoprotein A1
    • 10.35 ADAM 12
  • 11. Market Trends and Forecasts
    • 11.1 Ultrasensitive Cancer Tests
    • 11.2 Mergers and Acquisitions of Diagnostic Companies
    • 11.3 RT-PCR
    • 11.4 Genetic Tests of Hereditary Cancer Risk
    • 11.5 DNA Measurements
    • 11.6 Technical and Practical Issues for Potential New Markers
    • 11.7 Genetic Profiling
    • 11.8 Ploidy
    • 11.9 Advances in Sputum Analysis for Screening and Early Detection of Lung Cancer
    • 11.10 Pharmacogenetic Tests for Cancer
    • 11.11 Worldwide Healthcare Spending
    • 11.12 R&D Expenditures
    • Appendix 1: Web Links
    • Appendix 2: Cancer Information Resources
    • Appendix 3: Colon Cancer Staging
    • Appendix 4: Reimbursement for Tumor Marker Testing
    • Appendix 5: The Pathology of Prostate Cancer
    • Appendix 6: Government Regulation of Tumor Marker Tests
    • Appendix 7: Prevalence of Major Cancers in the U.S., 1999
    • Appendix 8: The Clinical Laboratory Improvement Act (CLIA)
    • Appendix 9: Marketers of Occult Blood Diagnostic Test Kits
  • List Of Figures
    • Figure 4.1: Model of Colorectal Cancer Development
    • Figure 4.2: The BTA stat Test vs. Cytology
  • List Of Tables
    • Table 2.1: Drug Development by Type of Cancer
    • Table 2.2: The 402 Organ Specific Medicines in Development for Cancer 2003
    • Table 2.3: Estimates for the Leading Sites of New Cancer Cases and Deaths in the U.S. by Sex, 2003
    • Table 2.4: Estimated Worldwide Number of New Cancer Cases and Deaths by Type of Cancer
    • Table 2.5: Estimated Number of New Cancer Cases and Deaths by Region
    • Table 2.6: Cancer Death Rates per 100,000 Population (and Rank) for All Cancer Sites by Country
    • Table 2.7: Cancer Associated Genes
    • Table 2.8: Carcinogens in the Workplace
    • Table 2.9: Private Funding Levels for the Biotechnology Segment
    • Table 2.10: Global Pharmaceutical Industry R&D Spending, 1995-2004
    • Table 2.11: U.S. Government NIH Research Budget, 1995-2004
    • Table 2.12: Herceptin Worldwide Sales, 1999-2005
    • Table 2.13: Classes of Drugs Used to Treat Breast Cancer
    • Table 3.1: In Vitro Cancer Marker Market Segments Worldwide
    • Table 3.2: Tumor Markers Currently in Common Use
    • Table 3.3: Global IVD Cancer Tumor Marker Testing Market Segments Projected Growth Rates, 2005-2010
    • Table 3.4: Worldwide Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2001-2010
    • Table 3.5: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2001-2010
    • Table 3.6: Worldwide In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
    • Table 3.7: U.S. In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
    • Table 3.8: Japanese In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
    • Table 3.9: European In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
    • Table 3.10: Global Distribution of IVD Cancer Tumor Marker Diagnostic Testing, 2005
    • Table 3.11: Estimated Market Share of Major Competitors in U.S. Cancer Tumor Marker Diagnostics Market
    • Table 3.12: Major Presence in Cancer Tumor Marker Diagnostics Markets
    • Table 3.13: Worldwide PSA Sales, 1997-2010
    • Table 3.14: U.S. PSA Sales, 2000-2010
    • Table 3.15: Serum Markers Used Clinically
    • Table 3.16: Drivers of IHC Growth
    • Table 3.17: Digene Product Revenues and Assets
    • Table 3.18: Worldwide Bladder Cancer Marker Sales, 2001-2010
    • Table 3.19: U.S. Bladder Cancer Marker Sales, 2001-2010
    • Table 3.20: Worldwide NMP-22 Sales, 2001-2010
    • Table 4.1: Colorectal Cancer Stages
    • Table 4.2: Worldwide CEA Sales, 2001-2010
    • Table 4.3: U.S. CEA Sales, 2001-2010
    • Table 4.4: Population Statistics of Serum Levels of PSA in Men Over 50 Years of Age
    • Table 4.5: PSA Doubling Time and Time to Reach PSA of 1,000
    • Table 4.6: PSA Doubling Times
    • Table 4.7: Worldwide CA19-9 Sales, 2001-2010
    • Table 4.8: U.S. CA19-9 Sales, 2001-2010
    • Table 4.9: Worldwide CA15-3 Sales, 2001-2010
    • Table 4.10: U.S. CA15-3 Sales, 2001-2010
    • Table 4.11: TPA Marker Sensitivity
    • Table 4.12: Worldwide CA-125 Sales, 2001-2010
    • Table 4.13: U.S. CA-125 Sales, 2001-2010
    • Table 4.14: Number of Pap Smears Performed by Country
    • Table 4.15: Lung Cancer Facts
    • Table 4.16: Patient Category Applications
    • Table 4.17: Worldwide AFP Marker Sales, 2001-2010
    • Table 4.18: U.S. AFP Cancer Marker Sales, 2001-2010
    • Table 4.19: Colorectal Cancer Monoclonal Antibody Imaging Kits
    • Table 6.1: Product Sales as a Percent of Total Product Sales
    • Table 6.2: Tumor Diagnosis Immunoassay
    • Table 6.3: Tumor Diagnosis Radioimmunoassay
    • Table 6.4: Summary of Matritech's Product Development Programs
    • Table 6.5: PBM Product List
    • Table 7.1: List and Discounted Prices for Abbott Tumor Marker Tests
    • Table 8.1: CPT Codes for Tumor Markers
    • Table 10.1: Familial Cancer Syndromes and Tumor Suppressor Genes
    • Table 10.2: Oncogenes and Anti-oncogenes
    • Table A3: TNM Classification
    • Table A7: Prevalence of Major Cancers
    • Table A8: Financial Comparison for Moderate and Waived CLIA Labs
    • Table A9: List of Marketers of Occult Blood Diagnostic Test Kits